NexImmune (STU:7370) Total Operating Expense: €18.73 Mil (TTM As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:7370 NexImmune Inc STU:7370
33 GF Score
Price €4.55
View Full Analysis

What is NexImmune Total Operating Expense?

NexImmune STU:7370 33 Total Operating Expense is €18.73 Mil as of Jun. 2024. GuruFocus rates STU:7370 with a GF Score™ of 33/100.

NexImmune's Total Operating Expense for the three months ended in Jun. 2024 was €2.54 Mil. NexImmune's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 was €18.73 Mil.

NexImmune Total Operating Expense Related Terms

NexImmune Total Operating Expense Historical Data

* Premium members only.

The historical data trend for NexImmune's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexImmune Total Operating Expense Chart

NexImmune Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Operating Expense
Get a 7-Day Free Trial 18.80 22.89 47.13 59.55 29.60

NexImmune Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.19 9.37 4.29 2.54 2.54
STU:7370
33GF Score
NexImmune Inc STU:7370
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NexImmune Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €18.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €18.73 Mil mean?
NexImmune (STU:7370) has a Total Operating Expense of €18.73 Mil as of Jun. 2024. Total operating expense is the primary recurring expense associated with central operations. View historical data on NexImmune and its competitors.
Is NexImmune's Total Operating Expense too high?
NexImmune's current Total Operating Expense is €18.73 Mil. Overall, NexImmune has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does NexImmune's Total Operating Expense compare to PPCBD and ENDV?
NexImmune's Total Operating Expense of €18.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on NexImmune and its competitors. NexImmune's current Total Operating Expense is €18.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexImmune stock overvalued right now?
NexImmune (STU:7370) has a current Total Operating Expense of €18.73 Mil. The current Total Operating Expense is €18.73 Mil. NexImmune's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For NexImmune (STU:7370), the current Total Operating Expense is €18.73 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NexImmune Business Description

Address 9119 Gaither Road, Gaithersburg, MD, USA, 20877
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
33GF Score

Get the complete analysis for STU:7370

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.55
Price